Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.

GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Nataliya Mar discussing real world toxicity profile of enfortumab vedotin with or without pembrolizumab in ...

An important unanswered question is whether rechallenging patients with enfortumab vedotin plus pembrolizumab after prior ICI exposure remains effective. The authors hypothesized that enfortumab ...

Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall ...

Neoadjuvant disitamab vedotin plus perioperative toripalimab has demonstrated efficacy in patients with HER2-expressing MIBC.

The agreement comes as Astellas is contemplating the end of patent protection for its top-selling prostate cancer product ... cancer therapy Padcev (enfortumab vedotin). Meanwhile, absorbing ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.